Eribulin
Checked 2026-09-09
Metastatic breast cancer after an anthracycline and a taxane; liposarcoma
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Eribulin Synthetic halichondrin B analogue (microtubule dynamics inhibitor) | 1.4 mg/m² (1.23 mg/m² as free base) | IV | D1, 8 |
Cycles
until progression
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Used in
HR-positive / HER2-negative breast cancerTriple-negative breast cancer (TNBC)Sarcomas (soft tissue, bone, GIST)
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
TC (docetaxel + cyclophosphamide)
Early breast cancer when an anthracycline is not wanted
every 21 days × 4
KEYNOTE-522 (pembrolizumab + chemotherapy, then adjuvant pembrolizumab)
Stage II-III triple-negative breast cancer
every 21 days × 4
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Sacituzumab govitecan
Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies
every 21 days
Capecitabine (post-neoadjuvant)
Residual invasive disease after neoadjuvant chemotherapy, HER2-negative
every 21 days × 6-8
Olaparib (adjuvant, OlympiA)
Germline BRCA1/2, HER2-negative, high-risk early breast cancer after chemotherapy
every 28 days × 13